All News

Found 764,340 articles

• BriaCell Announces Intention to Spin-Out Certain Pre-Clinical Assets into a Newly Created “SpinCo” Entity whereby Shareholders to Receive One New Share of “SpinCo” in Addition to Each Current Share of BriaCell Already Held

  3/30/2023

  BriaCell Therapeutics Corp. announces that its Board of Directors has unanimously approved a potential reorganization that would result in the spin-out of certain pre-clinical pipeline assets of the Company, specifically Bria-TILsRx™, and PKCδ inhibitors for multiple indications including cancer to an unlisted corporation to own the SpinCo Assets.

• Sustained Therapeutics Announces Second Phase II Trial of New Drug Platform

  3/30/2023

  A Vancouver-based therapeutics company has begun a second Phase II trial of its novel long lasting non-opioid pain medication, with a specific focus on treating Chronic Scrotal Pain (CSP), a debilitating condition estimated to affect 1% of the male population.

• ImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas

  3/30/2023

  ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) an AI-driven biotherapeutic research and technology company today announced a research collaboration and exclusive option license agreement with Xyphos Biosciences, Inc. (a wholly owned subsidiary of Astellas Pharma Inc., “Astellas”).

• Predictive Oncology Announces Collaboration with Integra Therapeutics to Advance Gene Therapy

  3/30/2023

  Predictive Oncology (NASDAQ: POAI), a science-driven company on the leading edge of oncology drug discovery and development, today announces it is partnering with Integra Therapeutics, a company focused on engineering the next generation of gene writing tools to cure diseases.

• Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma

  3/30/2023

  Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) today announced a clinical supply agreement with Roche to evaluate OTX-2002, its lead candidate in development for the treatment of MYC-driven hepatocellular carcinoma (HCC), in combination with Roche’s anti-PD-L1 therapy, atezolizumab, as part of Omega’s Phase 1/2 MYCHELANGELO™ I clinical trial.

• AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise

  3/30/2023

  AIM ImmunoTech Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases — including COVID-19, the disease caused by the SARS-CoV-2 virus — announced Nancy K. Bryan as the newest member of its Board of Directors.

• Jaguar Animal Health Exhibiting at Veterinary Cancer Society Collaborative Conference for Canalevia-CA1, the Company's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

  3/30/2023

  Jaguar Health, Inc. under its Jaguar Animal Health tradename for the veterinary market, announced that the Company is exhibiting at the Veterinary Cancer Society Collaborative Conference, which takes place April 19-22, 2023 in Cancun, Mexico, as part of ongoing promotional activities for Canalevia-CA1.

• Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants

  3/30/2023

  Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that the first participants were dosed in the Phase 2 study of VAX-24 in healthy infants.

• New Study of Neuvivo's NP001 is First to Link Regulation of the Innate Immune System with Respiratory Function in ALS Patients

  3/30/2023

  Neuvivo today announced the publication of a peer-reviewed paper titled: "Regulation of the Innate Immune System as a Therapeutic Approach to Supporting Respiratory Function in ALS".

• Avidity Biosciences Provides Regulatory Update on AOC 1001 for Myotonic Dystrophy Type 1 and Plans to Present Top-line Data from Phase 1/2 MARINA™ Trial at AAN Annual Meeting

  3/30/2023

  Avidity Biosciences, Inc. (Nasdaq: RNA) today provided an update on the Phase 1/2 MARINA™ trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1), an underrecognized, progressive and often fatal neuromuscular disease with no approved treatment options.

• NurExone Announces Q4 and Full-year 2022 Financial Results and Provides Company Update, Highlighting 143.9% Scientific Research Investment Growth

  3/30/2023

  NurExone Biologic Inc., a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, has released its financial results for 2022, the first since it became public last June.

• Validation of a Pragmatic Clinical Risk-Based Classification of NASH - New Supporting Real World Evidence from TARGET-NASH

  3/30/2023

  New research published today by real-world evidence leader Target RWE validates a practical risk-based classification of nonalcoholic fatty liver disease (NAFLD). "Validation of a Clinical Risk-Based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort," was published in the peer-reviewed publication Clinical Gastroenterology and Hepatology.

• Citryll Announces the Appointment of Paul Peter Tak as Chair of the Board of Directors

  3/30/2023

  Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat autoimmune and autoinflammatory diseases, announced that Dr. Paul Peter Tak, Citryll Board member since 2021, has been appointed Chair of the Board of Directors.

• IMUNON Reports 2022 Financial Results and Provides Business Update

  3/30/2023

  IMUNON, Inc. announced financial results for the year ended December 31, 2022, and provided an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 immunotherapy in Phase 2 clinical development for the treatment of advanced-stage ovarian cancer.

• Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq

  3/30/2023

  Apollomics Inc., a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced the completion of its business combination with Maxpro Capital Acquisition Corp.

• Stryker Now Offers the Only FDA-Cleared Pyrocarbon Bearing Material Option for Shoulder Hemiarthroplasty

  3/30/2023

  Stryker (NYSE:SYK), one of the world’s leading medical technology companies, today announced that Armodios M. Hatzidakis, MD, FAAOS, Western Orthopaedics, PC, Denver Surgery Center and Rose Medical Center, has successfully completed the first case in the United States, since the De Novo clearance, using the Tornier Pyrocarbon Humeral Head.

• Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium

  3/30/2023

  Lineage Cell Therapeutics, Inc. and the Christopher & Dana Reeve Foundation are proud to present the 1st Annual Spinal Cord Injury Investor Symposium, a forum to discuss the recent innovation, advancements, and challenges in the treatment of spinal cord injury.

• Integer Schedules First Quarter 2023 Earnings Release and Conference Call for April 27, 2023

  3/30/2023

  Integer Holdings Corporation announced that it plans to release financial and operational results for first quarter 2023, at 7 a.m. Central Time / 8 a.m. Eastern Time on Thursday, April 27, 2023.

• Neoadjuvant Opdivo (nivolumab) with Chemotherapy Demonstrates Long-Term, Durable Clinical Benefits for Patients with Resectable Non-Small Cell Lung Cancer at Three Years in the CheckMate -816 Trial

  3/30/2023

  Bristol Myers Squibb (NYSE: BMY) today announced three-year follow-up results from the Phase 3 CheckMate -816 trial, demonstrating sustained clinical benefits with three cycles of Opdivo (nivolumab) in combination with platinum-based chemotherapy for the neoadjuvant treatment of patients with resectable non-small cell lung cancer (NSCLC).

• GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection

  3/30/2023

  GSK plc (LSE/NYSE: GSK) and SCYNEXIS, Inc. (NASDAQ: SCYX), today announced they have entered into an exclusive licence agreement for Brexafemme (ibrexafungerp tablets), a US FDA approved, first-in-class antifungal for the treatment of vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC (RVVC).